Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Treatment regimen

Sacituzumab govitecan (Trodelvy)

Advanced triple-negative and HR-positive breast cancer after previous treatment

Updated: 28 October 20261 min read3 references

Summary for doctors

  • Advanced triple-negative breast cancer after at least two treatments (one for advanced disease) [1].
  • Neutropenia and severe diarrhoea are common (boxed warning) [2].
  • Its drug component is SN-38; UGT1A1*28 homozygotes are at greater risk of neutropenia [2, 3].

Dose and schedule

Sacituzumab govitecan

Advanced breast cancer (TNBC, or HR+ after endocrine therapy and chemotherapy)Cycle length: Every 21 days

Advanced breast cancer (TNBC, or HR+‎ after endocrine therapy and chemotherapy)

DrugDoseRouteSchedule
Sacituzumab govitecan10 mg/kgIV (first dose over 3 hours, then 1 to 2 hours)Days 1 and 8
Cycle length
Every 21 days
Duration
Until progression

As in ASCENT [1]; dose source: [2].

Evidence: ASCENT (2021)

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Premedication and supportive care

  • Premedication for infusion reactions and antiemetics (two or three drugs) [2].
  • Secondary G-CSF prophylaxis, or primary prophylaxis in high-risk patients; loperamide and atropine for diarrhoea.

Monitoring and dose adjustment

  • ANC below 1500 on day 1 or below 1000 on day 8: delay; febrile neutropenia: reduce the dose (7.5, then 5 mg/kg) [2].
  • Grade 3 to 4 diarrhoea: hold until recovery and reduce the dose [2].

Main evidence

Show detailsHide

ASCENT: median overall survival 12.1 vs 6.7 months with chemotherapy of the physician's choice [1].

Related cancer types

Breast cancer

Treatment regimens (physicians)

AC followed by paclitaxel (dose-dense and weekly)TC regimen (docetaxel and cyclophosphamide): dose and scheduleTCHP regimen: dose and schedule in HER2-positive breast cancerWeekly paclitaxel with trastuzumab (APT regimen)KEYNOTE-522 regimen: pembrolizumab and chemotherapy in triple-negative breast cancerTrastuzumab emtansine (T-DM1, Kadcyla): dose and scheduleTrastuzumab deruxtecan (T-DXd, Enhertu): dose and monitoringAdjuvant capecitabine after neoadjuvant treatment (CREATE-X)Pembrolizumab with chemotherapy in metastatic triple-negative breast cancer (KEYNOTE-355)

Physician tools and lessons

Cumulative Anthracycline Dose and Doxorubicin Equivalents10 cheap steps that save patients' livesBone-modifying agents in cancer: bone metastases, adjuvant use and osteonecrosis of the jawGermline genetic testing in cancer: who, and which genes?Management of brain metastasesFertility preservation before cancer treatmentMalignant pleural effusion: drainage, pleurodesis or an indwelling catheterCancer during pregnancy: chemotherapy and decisions

References

3 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerBardia A, Hurvitz SA, Tolaney SM, et al · N Engl J Med · 2021;384:1529-1541
    Study cardDOIPubMed Back to text: 1 2 3
  2. 2
    TRODELVY (SACITUZUMAB GOVITECAN) — Prescribing InformationGilead Sciences, Inc · FDA label · 2026
    Source Back to text: 1 2 3 4 5 6
  3. 3
    Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecanHulshof EC, Deenen MJ, Nijenhuis M, et al · Eur J Hum Genet · 2023;31:982-987
    DOIPubMed Back to text

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/sacituzumab-govitecan/

Related pages

27 October 2026 FOLFOX (mFOLFOX6): dose, schedule and side effects Dose and schedule of mFOLFOX6 (oxaliplatin 85, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), length of adjuvant treatment, premedication, neuropathy and dose adjustment. 27 October 2026 CAPOX (XELOX): dose, schedule and side effects Dose and schedule of CAPOX or XELOX (oxaliplatin 130 and capecitabine 1000 twice daily, days 1 to 14), length of adjuvant treatment, renal adjustment and side effects. 27 October 2026 FOLFIRI regimen: dose, schedule and side effects Dose and schedule of FOLFIRI (irinotecan 180, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), diarrhoea control, UGT1A1 and dose adjustment.